The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Vivimed Labs to clarify why segment-wise details were not submitted along with its financial results for the quarter ended 30 September 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company has not yet responded to the exchange's query. This is a routine compliance follow-up regarding the format of already-filed quarterly results, not a fresh penalty or investigation.
Short-term: minor negative sentiment as it highlights a compliance lapse in financial reporting. No material impact on business or share price expected unless the company fails to respond or further action is initiated by the exchange.